The global multiple myeloma market is anticipated to grow at a considerable CAGR of 4.8% during the forecast period. Myeloma is a cancer of plasma cells and majorly affects the kidney, bones, and blood cells. According to the Leukaemia & Lymphoma Society (LLS), an estimated 34,920 people living in the US is diagnosed with myeloma in 2021. The American Cancer Society estimates multiple myeloma in the US for 2023 and stated that about 35,730 new cases will be diagnosed in the US, among them 19,860 are men and 15,870 are women. About 12,590 mortalities are expected to occur by 2023, 7,000 in men and 5,590 in women. Dramatic advancements in new treatments, clinical trials, and new treatment approaches for myeloma are projected to drive market growth. For instance, in December 2022, a new drug modakafusp alfa was unveiled by researchers from the University of Pennsylvania’s Abramson Cancer Center. Patients in Phase I/II multicenter trials receiving 1.5 milligrams of modakafusp every four weeks, results in 43% decrease in cancer. Modakafusp is a fusion protein that targets interferon (a pro-inflammatory hormone that is also used for treating viral infections and other cancers) to cells that have CD38, a surface marker presents on myeloma cells and a variety of immune cells.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/multiple-myeloma-market
Additionally, the market players which include, Novartis, Pfizer, Sanofi, and others are inclined towards adopting various strategies such as partnership, collaboration, and funding to remain competitive in the global market. For instance, in March 2022, Sanofi and Blackstone announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) contribute up to $320million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa, to treat patients with multiple myeloma (MM). moreover, in January 2021 AbbVie and Teneobio, Inc. announced that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM).
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
- Segment Covered-
o By Drug Class
o By Type
o By Distribution Channel
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- including Abbott Laboratories, Amgen Inc., GlaxoSmithKline plc, Merck & Co., Novartis AG, and Others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Multiple Myeloma Market Report Segment
By Drug Class
- Immunomodulator
- Proteasome Inhibitor
- Anti-CD38 Monoclonal Antibody
- Alkylating Agents
- Others
By Type
- Hyperdiploid (HMM)
- Non-Hyperdiploid or hypodiploid
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
A full report of Multiple Myeloma Market available @ https://www.omrglobal.com/industry-reports/multiple-myeloma-market
Multiple Myeloma Market Report Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Aurobindo Pharma
- Aurobindo Pharma Ltd.
- Bristol-Myers Squibb Co.
- Cipla Inc.
- Eli Lilly and Co.
- Hoffmann-La Roche Ltd.
- Fresenius Kabi AG
- Genentech, Inc.
- Hikma Pharmaceuticals PLC
- Karyopharm Therapeutics Inc.
- Oncopeptides AB
- Ono Pharmaceutical Co., Ltd.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
